Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurology and Therapy
Published in: Neurology and Therapy 1/2012

Open Access 01-12-2012 | Original Research

A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada

Authors: Basil G. Bereza, Márcio Machado, Manny Papadimitropoulos, Beth Sproule, Arun V. Ravindran, Thomas R. Einarson

Published in: Neurology and Therapy | Issue 1/2012

Login to get access

Abstract

Introduction

Generalized anxiety disorder (GAD) is a chronic disease with waxing and waning of symptoms. This is the first comprehensive economic model developed to reflect the nature and course of GAD.

Methods

An incidence-based probabilistic Markov model was developed reflecting nine GAD health states (HS): clinical assessments (three HS), maintenance therapies (four HS), discontinuation (one HS), and death (one HS). A probability curve of the GAD onset (ages 18–80) determined entry into the model and assumed patients retained the diagnoses until death. Canadian Psychiatric Association (CPA) guidelines determined pharmacotherapy, with revisions/validation by an expert panel. Direct costs (clinician, pharmacotherapy, hospitalization) were retrieved from government publications. Remission was based on pooled-analysis of CPA-cited evidence. Remaining clinical rates, absenteeism, and hospitalization were retrieved from the literature. Direct costs were attributed throughout the model except for the discontinuation and death HS. Indirect costs (wage rate) were retrieved from government publications and the literature (absenteeism), and were attributed to patients with GAD ≤65 years of age. Results were discounted at 5% and results expressed in 2008 Canadian dollars.

Results

The mean lifetime cost of illness (COI) was estimated to be $31,213 (SD $9,100) per patient. The cost of absenteeism accounted for 96% of the mean COI. The mean age of onset was 31 years and approximately 19% did not respond to pharmacotherapy. Over 85% of patients discontinued treatment by the fourth cycle (2nd year of therapy). Over the course of the model, a mean of 53% of patients relapsed, with an average rate of 0.79 relapses per patient. On average and over a lifetime, the disorder went unmanaged over a period of 14 (SD 9) years. The model was most sensitive to absenteeism.

Conclusion

GAD is a costly disease with a lifetime COI <$32k/patient, with absenteeism exerting a significant impact.
Literature
1.
García-Altés A, Ondategui-Parra S, Neumann PJ. Cross national comparison of technology assessment processes. Int J Technol Assess Healthcare. 2004;20:300–10.
2.
Jacobi F, Wittchen H-U, Holting C, et al. Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med. 2004;34:597–611.PubMedCrossRef
3.
Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related conditions. Psychol Med. 2005;35:1747–59.PubMedCrossRef
4.
Bereza BG, Machado M, Einarson TR. Systematic review and quality assessment of economic evaluations and quality of life studies related to generalized anxiety disorder. Clin Ther. 2009;31:1279–308.PubMedCrossRef
5.
Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602.PubMedCrossRef
6.
Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617–27.PubMedCrossRef
7.
Offord DR, Boyle MH, Campbell D, et al. One-year prevalence of psychiatric disorder in Ontarians 15 to 64 years of age. Can J Psychiatry. 1996;41:559–63.PubMed
8.
Hales RE, Yudofsky SC, editors. The american psychiatric publishing textbook of clinical psychiatry. 4th ed. Arlington: American Psychiatric Publishing Inc.; 2003.
9.
Sadock BJ, Sadock VA, editors. Kaplan & Sadock’s comprehensive textbook of psychiatry. 8th ed. New York: Lippincott Williams & Wilkins; 2005.
10.
Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
11.
World Health Organization. The ICD-10 classification of mental and behavioral disorders: clinical description and diagnostic guidelines. Geneva: WHO; 1993.
12.
Canadian Psychiatric Association. Clinical practice guidelines: management of anxiety disorders. Can J Psychiatry. 2006;51:S1–92.
13.
von Neumann J, Morgenstern O. Theory of games and economic behavior. Princeton: Princeton University Press; 1947.
14.
Elwyn G, Edwards A, Eccles M, Rovner D. Decision analysis in patient care. Lancet. 2001;358:571–4.PubMedCrossRef
15.
16.
Le Roux H, Gatz M, Wetherall JL. Age at onset of generalized anxiety disorder in older adults. Am J Geriatr Psychiatry. 2005;13:23–30.PubMed
17.
18.
19.
Product Monograph: Alprazolam. Laval: ProDoc Lté; 2003.
20.
Product Monograph: Diazepam. Mississauga; Hoffmann-La Roche Ltd.; 2007.
21.
Prescribing Information: Lorazepam. St. Laurent: Wyeth Canada; 2003.
22.
Product Monograph: Apo-Paroxetine. Weston: Apotex Inc.; 2007.
23.
Product Monograph: Co-Sertraline. Mississauga: Cobalt Pharmaceuticals Inc; 2006.
24.
Product Monograph: Escitalopram. Montreal: Lundbeck Canada Inc.; 2008.
25.
Product Monograph: Venlafaxine. Montreal: Wyeth Canada; 2009.
26.
Product Monograph: Bromazepam. Mississauga: Hoffmann-La Roche Ltd.; 2007.
27.
Vasile RG, Bruce SE, Goisman RM, Pagano M, Keller MB. Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depress Anxiety. 2005;22:59–67.PubMedCrossRef
28.
Varia I, Rauscher F. Treatment of generalized anxiety disorder with citalopram. Int Clin Psychopharmacol. 2002;17:103–7.PubMedCrossRef
29.
Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59:211–5.PubMedCrossRef
30.
Gambi F, De Berardis D, Campanella D, et al. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol. 2005;19:483–7.PubMedCrossRef
31.
Gwynn RC, McQuistion HL, McVeigh KH, Garg RK, Frieden TR, Thorpe LE. Prevalence, diagnosis and treatment of depression and generalized anxiety disorder in a diverse urban community. Psychiatr Serv. 2008;6:641–7.CrossRef
32.
Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin. 2006;22:1825–37.PubMedCrossRef
33.
Bereza BG, Machado M, Ravindran AV, Einarson TR. Evidence based review of clinical outcomes of guideline recommended pharmacotherapies for generalized anxiety disorder (GAD). Can J Psychiatry (in press).
34.
Mullins CD, Shaya FT, Fanlun M, Wang J, Harrison D. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy. 2005;25:660–7.PubMedCrossRef
35.
Ohayon MM, Caulet M, Priest RG, Guilleminault C. Psychotropic medication consumption patterns in the UK general population. J Clin Epidemiol. 1998;51:273–83.PubMedCrossRef
36.
Yonkers KA, Bruce SE, Dyck IR, Keller MB. Chronicity, relapse and illness course of panic disorder, social phobia, and generalized anxiety disorder: Findings in men and women form 8 years of follow up. Depress Anxiety. 2003;17:173–9.PubMedCrossRef
37.
Ballenger J, Davidson J, Lecrubier Y, et al. Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatry. 2001;62:53–8.PubMed
38.
Martin JLR, Sainz-Pardo M, Furukawa TA, Martin-Sanchez E, Seone T, Galan C. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol. 2007;21:774–82.PubMedCrossRef
39.
Einarson TR. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Clin Ther. 1997;19:559–69.PubMedCrossRef
40.
41.
42.
43.
44.
45.
Kessler RC, DuPont RL, Berglund P, Wittchen H-U. Impairment in pure and co-morbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry. 1999;156:1915–23.PubMed
46.
47.
Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:629–40.PubMedCrossRef
48.
49.
Canadian Agency for Drugs and Technologies in Health. HTA; Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd ed. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.
50.
Krahn M, Naglie G, Naimark D, Redelmeier D, Detsky A. Primer on medical decision analysis: part 4—Analysing the model and interpreting the results. Med Decis Making. 1997;17:142–51.PubMedCrossRef
51.
Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22:209–12.CrossRef
52.
Alonso J, Petukhova M, Vilagut G, et al. Days out of role due to common physical and mental conditions: results from the WHO World Mental Health Surveys. Mol Psychiatry. 2010;16:1234–46.PubMedCrossRef
53.
Merikangas KR, Ames M, Cui L, et al. The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch Gen Psychiatry. 2007;64:1180–8.PubMedCrossRef
54.
Marciniak MD, Lage ML, Dunayevich ED, et al. The cost of treating anxiety: the medical and demographic correlates that impact total medical costs. Depress Anxiety. 2005;21:178–84.PubMedCrossRef
55.
Olfson M, Gameroff MJ. Generalized anxiety disorder, somatic pain and healthcare costs. Gen Hosp Psychiatry. 2007;29:310–6.PubMedCrossRef
56.
Schulberg HC, McClelland M, Coulehan JL, Block M, Werner G. Psychiatric decision making in family practice future research directions. Gen Hosp Psychiatry. 1986;8:1–6.PubMedCrossRef
57.
Wittchen H-U. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16:1622–710.CrossRef
58.
Roy-Byrne P, Wagner A. Primary care perspectives on generalized anxiety disorder. J Clin Psychiatry. 2004;65(Suppl. 13):20–6.PubMed
59.
Logue MB, Thomas AM, Barbee JG, et al. Generalized anxiety disorder patients seek evaluation for cardiological symptoms at the same frequency as patients with panic disorder. J Psychiatr Res. 1993;27:55–9.PubMedCrossRef
60.
Walker EA, Roy-Byrne PP, Katon WJ, et al. Psychiatric illness and irritable bowel syndrome: a comparison with inflammatory bowel disease. Am J Psychiatry. 1990;147:1656–61.PubMed
61.
Armstrong EP, Malone DC, Haim Erfer M. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major treatment disorder. Curr Med Res Opin. 2008;24:1115–21.PubMedCrossRef
Metadata
Title
A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada
Authors
Basil G. Bereza
Márcio Machado
Manny Papadimitropoulos
Beth Sproule
Arun V. Ravindran
Thomas R. Einarson
Publication date
01-12-2012
Publisher
Springer Healthcare Communications
Published in
Neurology and Therapy / Issue 1/2012
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-012-0001-y

Other articles of this Issue 1/2012

Neurology and Therapy 1/2012 Go to the issue

Original Research

Effect of Tetrabenazine on Motor Function in Patients with Huntington Disease

ORIGINAL RESEARCH

Virtual Reality Versus Conventional Treatment of Reaching Ability in Chronic Stroke: Clinical Feasibility Study

Review

The Impact of Spina Bifida on Caregivers

Original Research

The Human Body’s Own Language to be Considered for Safe and Effective Neurostimulation